|
Completed IT
development projects* |
Acquired
patents, li-censes and know-how |
Goodwill |
IT
development projects in progress* |
Total |
|
| |
DKK million |
DKK million |
DKK million |
DKK million |
DKK million |
|
|
|
|
|
|
|
|
| Cost at January 1, 2007 |
260 |
792 |
231 |
17 |
1,300 |
|
| Currency translation |
- |
(5) |
(10) |
- |
(15) |
|
| Acquisition of companies |
- |
328 |
316 |
- |
644 |
|
| Additions during the year |
- |
- |
- |
14 |
14 |
|
| Disposals during the
year |
(31) |
(104) |
- |
- |
(135) |
|
| Cost at December 31,
2007 |
229 |
1,011 |
537 |
31 |
1,808 |
|
|
|
|
|
|
|
|
| Amortization
and impairment losses at January 1, 2007 |
221 |
295 |
15 |
|
531 |
|
| Currency translation |
(1) |
(3) |
- |
|
(4) |
|
| Amortization for the year |
16 |
57 |
- |
|
73 |
|
| Impairment losses |
- |
- |
22 |
|
22 |
|
| Disposals for the year |
(31) |
(104) |
- |
|
(135) |
|
| Amortization
and impairment losses at December 31, 2007 |
205 |
245 |
37 |
- |
487 |
|
|
|
|
|
|
|
|
| Carrying
amount at December 31, 2007 |
24 |
766 |
500 |
31 |
1,321 |
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Cost at January 1, 2006 |
247 |
465 |
135 |
20 |
867 |
|
| Currency translation |
(1) |
1 |
(8) |
- |
(8) |
|
| Acquisition of
companies |
- |
324 |
104 |
- |
428 |
|
| Additions during the
year |
3 |
2 |
- |
8 |
13 |
|
| Transfer from other
items |
11 |
- |
- |
(11) |
- |
|
| Cost at December 31,
2006 |
260 |
792 |
231 |
17 |
1,300 |
|
|
|
|
|
|
|
|
| Amortization
and impairment losses at January 1, 2006 |
195 |
226 |
15 |
|
436 |
|
| Currency translation |
(1) |
- |
- |
|
(1) |
|
| Amortization for the
year |
27 |
54 |
- |
|
81 |
|
| Impairment losses
for the year |
- |
15 |
- |
|
15 |
|
| Amortization
and impairment losses at December 31, 2006 |
221 |
295 |
15 |
- |
531 |
|
| |
|
|
|
|
|
|
| Carrying
amount at December 31, 2006 |
39 |
497 |
216 |
17 |
769 |
|
|
|
|
|
|
|
|
| *
Assets developed internally |
| |
|
|
|
|
|
|
| The carrying amount of intangible assets, including goodwill, was
reviewed for impairment losses at December 31, 2007. This did not reveal any
need to write down the book values for impairment but during the year a
write-down of DKK 22 million based on a concrete valuation of a goodwill
asset related to streptococcal-based production of hyaluronic acid in China. |
| |
|
|
| The impairment tests compared the discounted cash flow of the
individual cash-generating units with the carrying amounts of the units. Cash
flow is based on budgets and business plans for the period 2008-2018. |
| |
|
|
| Material assumptions used in calculating the terminal value is
based on an assumptions of a individual unit are as follows: |
| |
|
|
|
|
Biopharmaceuticals |
|
| |
|
|
Microorganisms |
ingrediens |
|
| Expected
growth in turnover |
|
10% |
|
10-15% |
|
| Growth in sales terminal value |
|
3% |
|
6% |
|
| Discount factor |
|
12% |
|
15% |
|
|
|
|
|
|
